Trial abstracts in the registry — page 9
700 documents of type trial abstract.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease randomising 218 participants over 24 weeks. Primary result…
Moderate02 Feb 2024 -
Randomised crossover, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low01 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low29 Jan 2024 -
Randomised crossover, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low29 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low28 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low27 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Jan 2024 -
Single-arm open-label, phase 1 study of CJC-1295 in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low23 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low21 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low20 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes randomising 703 participants over 26 weeks. Primary result…
High19 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low19 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity randomising 3,731 participants over 56 weeks. Primary result: Mean change −8.0 %…
High18 Jan 2024 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low18 Jan 2024 -
Randomised crossover, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low18 Jan 2024 -
Observational, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low18 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Retatrutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low17 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes randomising 495 participants over 24 weeks. Primary result: Reduction of…
High16 Jan 2024 -
Randomised crossover, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low12 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation randomising 361 participants over 28 days. Primary result: A…
Moderate09 Jan 2024 -
Randomised crossover, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Jan 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low08 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low08 Jan 2024 -
Observational, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jan 2024 -
Randomised crossover, phase 1 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Jan 2024 -
Single-arm open-label, phase 2 study of Liraglutide in mash over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low04 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition randomising 45 participants over 3 months. Primary result: No significant…
Low01 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low30 Dec 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes randomising 9,340 participants over median 3.8 years…
High28 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low28 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 2 diabetes randomising 656 participants over 52 weeks. Primary result: A modest…
Moderate24 Dec 2023
page 9 of 18